The escalation cohorts will evaluate escalating dose levels of ASP8374 in a total of approximately 33 dose limiting toxicity (DLT)-evaluable participants. If a confirmed response (partial response (PR) or complete response(CR)) occurs in a monotherapy escalation cohort, a tumor specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable.